French National Institute of Health and Medical Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile

French National Institute of Health and Medical Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH1255460D
  • |
  • Pages: 86
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immunology, inflammation, genetics, cancer, infectiology and microbiology, physiopathology, public health, health technologies, metabolism, cell biology and immunology, among others. It provides services in the areas of human diseases and research findings to the medical community, and to both national and international partners. INSERM also conducts translational research and development services. It operates research units and research centers. INSERM is headquartered in Paris, France.

French National Institute of Health and Medical Research-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

French National Institute of Health and Medical Research, Medical Devices Deals, 2012 to YTD 2018 12

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deal Details 18

Venture Financing 18

Therachon Raises USD60 Million in Mezzanine Financing 18

ILiAD Biotech Raises USD0.6 Million in Venture Financing 20

Step Pharma Raises Additional USD10.1 Million in Series A Financing 21

ILiAD Biotech Raises USD4.7 Million in Financing 23

ILiAD Biotech Raises USD1.2 Million in Venture Financing 24

Therachon Raises Additional USD5 Million in Series A Financing Round 25

ILiAD Biotech Raises USD0.5 Million in Venture Financing 26

ILiAD Biotech Raises USD1 Million in Venture Financing 27

Inception IBD Raises USD14.1 Million in Series A Financing 28

ILiAD Biotech Raises USD0.6 Million in Venture Financing 29

Therachon Raises USD35 Million in Series A Financing 30

Eyevensys Secures Venture Funding 31

Sensorion Raises USD4.6 Million in Venture Financing 32

AAVLife Raises USD 12 Million In Series A Financing 33

Aelis Farma Raises USD1.7 Million in Venture Financing 34

Inotrem Raises USD 25 Million In Series A Financing 35

Hemarina Raises USD 8 Million In Series B Financing 37

Eyevensys Raises USD 2 Million In First Round Of Financing 38

Partnerships 39

Telix Pharma Enters into Research Agreement with INSERM and ARRONAX 39

Genisphere Enters into Agreement with Inserm 40

TxCell Enters into R&D Agreement with Inserm Transfert 41

Evotec Enters into Research Agreement with Inserm Transfert 42

Pierre Fabre Medicament Partners with Inserm Transfert 43

AstraZeneca Enters into Research Agreement with Inserm 44

Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 45

Mifcare Enters into Agreement with Inserm 46

DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 47

Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 49

Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 51

Licensing Agreements 53

OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 53

Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 54

TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 55

ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 56

Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 57

Brainvectis Enters into Licensing Agreement with INSERM 58

ProGeLife Enters into Licensing Agreement with University of Bordeaux and INSERM Transfert 59

Inserm Transfert Enters into Licensing Agreement with HalioDx 60

Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 61

IntegraGen Enters into Licensing Agreement with Inserm 63

AAVLife Amends Licensing Agreement with Inserm Transfert 64

Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 65

Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 66

PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 67

GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 68

Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 69

GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 70

GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 72

ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 74

Equity Offering 75

Horama Spin off from Inserm Transfert 75

French National Institute of Health and Medical Research-Key Competitors 76

French National Institute of Health and Medical Research-Key Employees 77

French National Institute of Health and Medical Research-Locations And Subsidiaries 78

Head Office 78

Other Locations & Subsidiaries 78

Affiliate 78

Recent Developments 79

Government and Public Interest 79

Sep 03, 2018: Gene-hunters make sense of a new immune disease 79

Aug 31, 2018: Novel brain network linked to chronic pain in Parkinson's disease 81

May 02, 2018: Discovery of a first genetic cause of Whipple's disease 82

Apr 26, 2018: Discovery of a future therapy for hemoglobinopathies 83

Dec 20, 2017: NORD Awards Five New Grants for Rare Disease Research 84

Other Significant Developments 85

Aug 20, 2018: Bioengineered tooth replacement opens doors to new therapies 85

Appendix 86

Methodology 86

About GlobalData 86

Contact Us 86

Disclaimer 86

List of Figures

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

French National Institute of Health and Medical Research, Medical Devices Deals, 2012 to YTD 2018 12

List of Tables

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Key Facts 2

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

French National Institute of Health and Medical Research, Deals By Therapy Area, 2012 to YTD 2018 10

French National Institute of Health and Medical Research, Medical Devices Deals, 2012 to YTD 2018 12

French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Therachon Raises USD60 Million in Mezzanine Financing 18

ILiAD Biotech Raises USD0.6 Million in Venture Financing 20

Step Pharma Raises Additional USD10.1 Million in Series A Financing 21

ILiAD Biotech Raises USD4.7 Million in Financing 23

ILiAD Biotech Raises USD1.2 Million in Venture Financing 24

Therachon Raises Additional USD5 Million in Series A Financing Round 25

ILiAD Biotech Raises USD0.5 Million in Venture Financing 26

ILiAD Biotech Raises USD1 Million in Venture Financing 27

Inception IBD Raises USD14.1 Million in Series A Financing 28

ILiAD Biotech Raises USD0.6 Million in Venture Financing 29

Therachon Raises USD35 Million in Series A Financing 30

Eyevensys Secures Venture Funding 31

Sensorion Raises USD4.6 Million in Venture Financing 32

AAVLife Raises USD 12 Million In Series A Financing 33

Aelis Farma Raises USD1.7 Million in Venture Financing 34

Inotrem Raises USD 25 Million In Series A Financing 35

Hemarina Raises USD 8 Million In Series B Financing 37

Eyevensys Raises USD 2 Million In First Round Of Financing 38

Telix Pharma Enters into Research Agreement with INSERM and ARRONAX 39

Genisphere Enters into Agreement with Inserm 40

TxCell Enters into R&D Agreement with Inserm Transfert 41

Evotec Enters into Research Agreement with Inserm Transfert 42

Pierre Fabre Medicament Partners with Inserm Transfert 43

AstraZeneca Enters into Research Agreement with Inserm 44

Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 45

Mifcare Enters into Agreement with Inserm 46

DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 47

Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 49

Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 51

OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 53

Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 54

TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 55

ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 56

Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 57

Brainvectis Enters into Licensing Agreement with INSERM 58

ProGeLife Enters into Licensing Agreement with University of Bordeaux and INSERM Transfert 59

Inserm Transfert Enters into Licensing Agreement with HalioDx 60

Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 61

IntegraGen Enters into Licensing Agreement with Inserm 63

AAVLife Amends Licensing Agreement with Inserm Transfert 64

Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 65

Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 66

PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 67

GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 68

Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 69

GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 70

GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 72

ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 74

Horama Spin off from Inserm Transfert 75

French National Institute of Health and Medical Research, Key Competitors 76

French National Institute of Health and Medical Research, Key Employees 77

French National Institute of Health and Medical Research, Subsidiaries 78

French National Institute of Health and Medical Research, Affiliate 78

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

French National Institute of Health and Medical Research, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17815
Site License
USD 500 INR 35630
Corporate User License
USD 750 INR 53445

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com